BTG Share Discussion Threads

[adejuk] 03/5/2012 15:34

this is looking toppy now
out until it fills the gap back at 340
i hope!

[fhmktg] 30/4/2012 18:16

We'll see how the sales grow!
Still good news!
I'm keen to hear of trials for DELIBERATE high dosing with Methotrexate - knocking back with Voraxaze - much bigger market!
Trial use in Rheumatoid arthiritis would be welcome as well.

[gregmorg] 30/4/2012 14:04

Yes fhmtg, BTG did indeed state direct marketing of this one in January in the Interim Statement although it went on and said it anticipated peak sales of $15m in the US.They also highlighted a Japanese deal.Maybe ASD has a greater distribution capability in the USA than the current BTG sales force and its more cost effective for now.

[fhmktg] 30/4/2012 13:39

Voraxaze launched today - good news, but I was surprised to see them using a distributor.
I thought they were going to use their own sales force.

[cortez4] 29/4/2012 12:13

This was an agreement with Tolerx 2001 and concerns only the IP.

[cockneytrader] 29/4/2012 11:04

if the patent expires why would anyone continue to pay the license? it just would not happen!

the only time this would arise is when new patents are taken out as the process or design of a product evolves - for example the torotrak technology has evolved and hundreds more patents have been taken out.

torotrak was an old btg chestnut, spun off many years ago.

[cumnor] 29/4/2012 10:12

Why not Cortez. Is'nt it down to the specifics of the agreement? You may be right but every licensing agreement is different, with each party wanting to maximise it's exposure to any potential future gains.

Interesting area anyhow. As pharmas are under more pressure than ever with most now turning to alternative uses for established products, trialling them anew to extend period of generic free competition if sucessful rather than developing new products from scratch-almost impossible.

Will heighten the distinction between 'regulatory' and 'patent' protection and no doubt give the laweyrs more work than ever.

[bargainbob] 29/4/2012 08:33

Of course they can.

[cortez4] 28/4/2012 23:14

This is how it works. BTG licence the patents early in development, before pI. The licencee is now responsible for development through pI, pII, pIII, approval and marketing. This may cost $m's and they run the risks of losses re failure or poor sales. BTG pay nothing towards this, they merely collect milestone payments and royalties if marketed.

Is it likely BTG deserve or could negotiate further ongoing monetary agreements for after the patents expire? I don't think so.

[cortez4] 28/4/2012 22:58

Anyone in doubt about royalties ending on patent expirey should contact Andy Burrows at BTG, he usually answers e-mails quite promptly.

[cockneytrader] 28/4/2012 22:28

Patents expire. When expired they are worthless. Any drug company can then reproduce the recipe and flog it.

Admittedly patents on complex bio drugs (involving cloned sheeps and the like) may expire but barriers to entry in these markets remain high, therefore no competition.

[cumnor] 28/4/2012 20:40

They don't need to. Still not convinced re patent cortez. Surely licensing or marketing agreements will be tailored differently for each deal and mgts take on a products potential, or clauses for continuing involvement perhaps at a reduced rate. Not really sure? imo dyor

[cortez4] 28/4/2012 18:23

txi, anyone could make a generic drug but BTG won't.

[txi] 28/4/2012 11:24

Cortez - In regard to the patent expiry. Are BTG then able to produce and sell the drugs that have expired? They would certainly have the clinical know how.

[cortez4] 28/4/2012 00:15

And the same with Benefix, BTG's patents have expired so the royalties cease. It doesn't matter what improvement or sales progress any licenced product achieves after BTG's patents have expired, it will not benefit BTG.

[cortez4] 27/4/2012 23:42

cunmore, because that is what BTG's original business model was based on, Intellectual Property (IP or patents). BTG do not licence the technology (eg Lemtrada), they licence the patents to Lemtrada. And once the patents expire, so do BTG's rights to royalties.

It's the same with Zytiga, but because BTG's Zytiga patents last from the early to mid 2020's, there's much more chance of royalties to grow on that products progress.

[cumnor] 27/4/2012 22:55

Cortez, re patent expiry how are you so sure of what is in the specific agreement?

[bargainbob] 27/4/2012 17:47

Just look at the Big guys, we are chicken feed. IMHO

Johnston and Johnston $175.4 billion
Pfizer $170.5 billion
Roche $158.5 billion
Novartis $150.6 billion
GlaxoSmithKline $118.5 billion
Merck $116 billion
Sanofi $100 billion
Abbot $95.5billion
AstraZeneca $58.2 billion
Bristol Myers $57.3 billion
Eil Lily 46.4 Billion

[cortez4] 27/4/2012 17:06

Maybe but the link 20264 states '....expire on December 8, 2015, and international counterparts.' So it looks like the US patents and possibly others expire in Dec 2015. Once BTG's patents have expired, royalties cease no matter what happens with the product afterward. So any improvement in Lemtrada or Lemtrada sales after Dec 2015 will not benefit BTG if their patents have expired.

Zytiga is more like it with patents lasting from early to the mid 2020's.

[doctor 69] 27/4/2012 13:26

I think 2017

[cortez4] 27/4/2012 12:29

When BTG's patents for Lemtrada (or any other licenced product) expire the royalties cease as happened with Benefix recently.

[cumnor] 26/4/2012 23:00

No idea BB. Now the trials are out of the way I presume the main clinical expense is as well, unless the FDA get thick. After that it's pure marketing which may not be that expensive (compared to for ex another BP drug or CVS tablet in general practice where the market is saturated and so serious marketing is required).

I think the medical (not consumer) market for Varisolve will be narrow-vascular surgeons, maybe radiologists, expense concious HMOs and Insurers and then slowly raising awareness with some consumer marketing (in the US) and primary care.

It is somewhat unique and a first (regulated) of it's kind so the important guys will already be aware of it. I believe you are sometimes better cutting a deal with the big guys with huge marketing clout, contacts and know-how. Because it is virtually past P3 any deal would have to be on excellent terms for BGC. Don't know how big or good BTG's US team is-maybe it can do alone. imo

[bargainbob] 26/4/2012 22:40

Cumnor

Even a partial sale could happen. Re Varisolve how much will BGC need to raise in order to do a proper Launch. 50 million ?

[cumnor] 26/4/2012 22:37

Interesting BB, but the fact they are all on the look for acquisitons (like AZN's and GSK's recent foray as well) is also good news. Only a matter of time I think.